Losses of Both Products of the Cdkn2a/Arf Locus Contribute to Asbestos-Induced Mesothelioma Development and Cooperate to Accelerate Tumorigenesis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The CDKN2A/ARF locus encompasses overlapping tumor suppressor genes p16(INK4A) and p14(ARF), which are frequently co-deleted in human malignant mesothelioma (MM). The importance of p16(INK4A) loss in human cancer is well established, but the relative significance of p14(ARF) loss has been debated. The tumor predisposition of mice singly deficient for either Ink4a or Arf, due to targeting of exons 1α or 1β, respectively, supports the idea that both play significant and nonredundant roles in suppressing spontaneous tumors. To further test this notion, we exposed Ink4a(+/-) and Arf(+/-) mice to asbestos, the major cause of MM. Asbestos-treated Ink4a(+/-) and Arf(+/-) mice showed increased incidence and shorter latency of MM relative to wild-type littermates. MMs from Ink4a(+/-) mice exhibited biallelic inactivation of Ink4a, loss of Arf or p53 expression and frequent loss of p15(Ink4b). In contrast, MMs from Arf(+/-) mice exhibited loss of Arf expression, but did not require loss of Ink4a or Ink4b. Mice doubly deficient for Ink4a and Arf, due to deletion of Cdkn2a/Arf exon 2, showed accelerated asbestos-induced MM formation relative to mice deficient for Ink4a or Arf alone, and MMs exhibited biallelic loss of both tumor suppressor genes. The tumor suppressor function of Arf in MM was p53-independent, since MMs with loss of Arf retained functional p53. Collectively, these in vivo data indicate that both CDKN2A/ARF gene products suppress asbestos carcinogenicity. Furthermore, while inactivation of Arf appears to be crucial for MM pathogenesis, the inactivation of both p16(Ink4a) and p19(Arf) cooperate to accelerate asbestos-induced tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“~70% of MM exhibits p16INK4A homozygous deletion [4,[24], [25], [26], [27], [28]]”
From Asbestos conceives Fe(II)-dependent mutagenic stromal milieu through ceaseless macrophage ferroptosis and β-catenin induction in mesothelium (2020) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, we sought for possible links between β-catenin signal activation and p16INK4A deletion, a largest target gene of MM carcinogenesis [4,[24], [25], [26], [27], [28]].”
From Asbestos conceives Fe(II)-dependent mutagenic stromal milieu through ceaseless macrophage ferroptosis and β-catenin induction in mesothelium (2020) · cites this paper as [24]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“129-Cdkn2a) [4] mice were from the Mouse Figure 2.”
BackgroundTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
(1999) · PubMed · Cited by 338
The differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis
Sharpless, N. E., Ramsey, M. R., Balasubramanian, P., Castrillon, D. H., & DePinho, R. A. (2004) · Oncogene · doi:10.1038/sj.onc.1207074 · Cited by 224
Heintz, N. H., Janssen-Heininger, Y. M. W., & Mossman, B. T. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0206tr · Cited by 182
Poulikakos, P. I., Xiao, G.-H., Gallagher, R., Jablonski, S., Jhanwar, S. C., & Testa, J. R. (2006) · Oncogene · doi:10.1038/sj.onc.1209587 · Cited by 178
Self-citationA Mouse Model Recapitulating Molecular Features of Human Mesothelioma
Altomare, D. A., Vaslet, C. A., Skele, K. L., De Rienzo, A., Devarajan, K., Jhanwar, S. C., McClatchey, A. I., Kane, A. B., & Testa, J. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2312 · Cited by 153
Self-citationA Conditional Mouse Model for Malignant Mesothelioma
Jongsma, J., van Montfort, E. H. N., Vooijs, M., Zevenhoven, J., Krimpenfort, P., van der Valk, M., van de Vijver, M. J., & Berns, A. J. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.030 · Cited by 138
Testa, J. R., Getts, L. A., Salazar, H., Liu, Z., Handel, L. M., Godwin, A. K., & Hamilton, T. C. (1994) · PubMed · Cited by 110
Self-citation
Cited by
Molecular pathogenesis of malignant mesothelioma
Sekido, Y. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt166 · Cited by 279
Napolitano, A., Pellegrini, L., Dey, A., Larson, D., Tanji, M., Flores, E. G., Kendrick, B., Lapid, D., Powers, A., Kanodia, S., et al. (2016) · Oncogene · doi:10.1038/onc.2015.243 · Cited by 161
Self-citationGermline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1328 · Cited by 144
“55 weeks in WT mice, respectively) is similar to the accelerated onset and shorter median survivals that we observed previously in mice with haploinsufficiency for other tumor suppressor genes—Cdkn2a/p16(Ink4a), Cdkn2a/p19Arf, and Nf2— that are thought to act as key drivers in malignant mesothelioma pathogenesis (30,…”
Self-citationMossman, B. T., Shukla, A., Heintz, N. H., Verschraegen, C. F., Thomas, A., & Hassan, R. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.12.028 · Cited by 107
Carbone, M., Pass, H. I., Ak, G., Alexander, H. R., Baas, P., Baumann, F., Blakely, A. M., Bueno, R., Bzura, A., Cardillo, G., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.03.014 · Cited by 97
Self-citationKadariya, Y., Menges, C. W., Talarchek, J., Cai, K. Q., Klein-Szanto, A. J., Pietrofesa, R. A., Christofidou-Solomidou, M., Cheung, M., Mossman, B. T., Shukla, A., et al. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0347 · Cited by 89
Self-citationA Novel and Stable Mouse Artificial Chromosome Vector
Takiguchi, M., Kazuki, Y., Hiramatsu, K., Abe, S., Iida, Y., Takehara, S., Nishida, T., Ohbayashi, T., Wakayama, T., & Oshimura, M. (2012) · ACS Synthetic Biology · doi:10.1021/sb3000723 · Cited by 81
New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
Rossini, M., Rizzo, P., Bononi, I., Clementz, A. G., Ferrari, R., Martini, F., & Tognon, M. G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00091 · Cited by 74
Kukuyan, A.-M., Sementino, E., Kadariya, Y., Menges, C. W., Cheung, M., Tan, Y., Cai, K. Q., Slifker, M. J., Peri, S., Klein–Szanto, A. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-4093 · Cited by 67
Self-citationThe role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma
de Assis, L. V. M., Locatelli, J., & Isoldi, M. C. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.008 · Cited by 66
Menges, C. W., Kadariya, Y., Altomare, D. A., Talarchek, J. N., Neumann-Domer, E., Wu, Y., Xiao, G., Shapiro, I. M., Kolev, V. N., Pachter, J. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2062 · Cited by 60
Self-citationBononi, A., Napolitano, A., Pass, H. I., Yang, H., & Carbone, M. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1081066 · Cited by 59
Self-citationAndujar, P., Lacourt, A., Brochard, P., Pairon, J. ‐., Jaurand, M., & Jean, D. (2016) · Journal of Toxicology and Environmental Health Part B · doi:10.1080/10937404.2016.1193361 · Cited by 60
New therapeutic strategies for malignant pleural mesothelioma
Bonelli, M. A., Fumarola, C., Monica, S. L., & Alfieri, R. R. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.07.012 · Cited by 57
Pietrofesa, R. A., Velalopoulou, A., Arguiri, E., Menges, C. W., Testa, J. R., Hwang, W.-T., Albelda, S. M., & Christofidou-Solomidou, M. (2016) · Carcinogenesis · doi:10.1093/carcin/bgv174 · Cited by 56
Self-citationCombined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice
Badhai, J., Pandey, G. K., Song, J.-Y., Krijgsman, O., Bhaskaran, R., Chandrasekaran, G., Kwon, M.-C., Bombardelli, L., Monkhorst, K., Grasso, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191257 · Cited by 49
Ito, F., Yanatori, I., Maeda, Y., Nimura, K., Ito, S., Hirayama, T., Nagasawa, H., Kohyama, N., Okazaki, Y., Akatsuka, S., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101616 · Cited by 45
Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma
Sneddon, S., Patch, A., Dick, I. M., Kazakoff, S. H., Pearson, J. V., Waddell, N., Allcock, R. J. N., Holt, R. A., Robinson, B. W. S., & Creaney, J. (2017) · BMC Cancer · doi:10.1186/s12885-017-3382-6 · Cited by 42
Bronte, G., Incorvaia, L., Rizzo, S., Passiglia, F., Galvano, A., Rizzo, F., Rolfo, C. D., Fanale, D., Listì, A., Natoli, C., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.011 · Cited by 41
Preclinical Models of Malignant Mesothelioma
Testa, J. R., & Berns, A. J. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00101 · Cited by 40
Self-citationKalra, N., Zhang, J., Thomas, A., Xi, L., Cheung, M., Talarchek, J. N., Burkett, S. S., Tsokos, M., Chen, Y., Raffeld, M. A., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1362-2 · Cited by 34
Self-citationUse of preclinical models for malignant pleural mesothelioma
Shamseddin, M., Obacz, J., Garnett, M. J., Rintoul, R. C., Francies, H. E., & Marciniak, S. J. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-216602 · Cited by 32
Kettunen, E., Savukoski, S., Salmenkivi, K., Böhling, T., Vanhala, E., Kuosma, E., Anttila, S. L., & Wolff, H. J. (2019) · BMC Cancer · doi:10.1186/s12885-019-5652-y · Cited by 31
Walter, R. F. H., Mairinger, F. D., Ting, S. C., Vollbrecht, C., Mairinger, T., Theegarten, D., Christoph, D. C., Schmid, K. W., & Wohlschlaeger, J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.27 · Cited by 30
Klorin, G., Rozenblum, E., Glebov, O. K., Walker, R. L., Park, Y. S., Meltzer, P. S., Kirsch, I. R., Kaye, F. J., & Roschke, A. V. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.04.006 · Cited by 30
Pathological and molecular biological approaches to early mesothelioma
Tsujimura, T., Torii, I., Sato, A., Song, M., Fukuoka, K., Hasegawa, S., & Nakano, T. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0369-1 · Cited by 29
Hong, S., Li, X., Zhao, Y., Yang, Q., & Kong, B. (2012) · Oncology Reports · doi:10.3892/or.2012.1641 · Cited by 29
Luo, Y., Jianjun, D., Cui, Y., Li, T., Bai, J., Huang, L., Sun, Y., Dong, F., & Zhang, Q. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.07.033 · Cited by 26
Mesothelioma: Identical Routes to Malignancy from Asbestos and Carbon Nanotubes
Port, J., & Murphy, D. J. (2017) · Current Biology · doi:10.1016/j.cub.2017.07.026 · Cited by 26
Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment
Febres‐Aldana, C. A., Fanaroff, R. E., Offin, M. D., Zauderer, M. G., Sauter, J. L., Yang, S., & Ladanyi, M. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042420-092719 · Cited by 25
DNA repair systems in malignant mesothelioma
Toumpanakis, D., & Theocharis, S. E. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.021 · Cited by 24
Mesotheliomas in Genetically Engineered Mice Unravel Mechanism of Mesothelial Carcinogenesis
Jean, D., & Jaurand, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082191 · Cited by 24
Asbestos: Modern Insights for Toxicology in the Era of Engineered Nanomaterials
Felley-Bosco, E., & MacFarlane, M. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00146 · Cited by 23
Resveratrol contributes to chemosensitivity of malignant mesothelioma cells with activation of p53
Lee, Y.-J., Park, I.-S., Lee, Y.-J., Shim, J., Cho, M. K., Nam, H.-S., Park, J. W., Oh, M.-H., & Lee, S.-H. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.11.004 · Cited by 22
Tolani, B., Acevedo, L. A., Hoang, N. T., & He, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010238 · Cited by 23
Lung Cancer: Mechanisms of Carcinogenesis by Asbestos
Mossman, B. T., & Gualtieri, A. F. (2020) · Springer eBooks · doi:10.1007/978-3-030-30766-0_12 · Cited by 21
Nuvoli, B., Santoro, R., Catalani, S., Battistelli, S., Benedetti, S., Canestrari, F., & Galati, R. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-24 · Cited by 17
Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling
Novelli, F., Yoshikawa, Y., Vitto, V. A. M., Modesti, L., Minaai, M., Pastorino, S., Emi, M., Kim, J.-H., Kricek, F., Bai, F., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2405231121 · Cited by 17
Self-citationP14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
Pezzuto, F., Lunardi, F., Vedovelli, L., Fortarezza, F., Urso, L., Grosso, F., Ceresoli, G. L., Kern, I., Vlačić, G., Faccioli, E., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.653497 · Cited by 16
DNA repair and damage pathways in mesothelioma development and therapy
Malakoti, F., Targhazeh, N., Abadifard, E., Zarezadeh, R., Samemaleki, S., Asemi, Z., Younesi, S., Mohammadnejad, R., Hossini, S. H., Karimian, A., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02597-9 · Cited by 16
Cheung, M., Kadariya, Y., Pei, J., Talarchek, J. N., Facciolo, F., Visca, P., Righi, L., Cozzi, I., Testa, J. R., & Ascoli, V. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.07.004 · Cited by 14
Self-citationOkazaki, Y. (2021) · Pathology International · doi:10.1111/pin.13196 · Cited by 12
Okamoto, S., Jiang, Y., Kawamura, K., Shingyoji, M., Fukamachi, T., Tada, Y., Takiguchi, Y., Tatsumi, K., Shimada, H., Hiroshima, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060297 · Cited by 11
Lee, Y.-J., Park, K.-S., Heo, S., Nam, H.-S., Cho, M. K., & Lee, S.-H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01181-6 · Cited by 10
Cheung, M., Menges, C. W., & Testa, J. R. (2017) · Current cancer research · doi:10.1007/978-3-319-53560-9_8 · Cited by 9
Self-citationAsbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma
Farahmand, P., Gyurászová, K., Rooney, C., Iraolagoitia, X. L. R., Jayasekera, G., Hedley, A., Johnson, E. R., Chernova, T. A., Malviya, G., HALL, H. G., et al. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1200650 · Cited by 9
Cell Signaling and Epigenetic Mechanisms in Mesothelioma
Mossman, B. T. (2017) · Current cancer research · doi:10.1007/978-3-319-53560-9_10 · Cited by 8
Cui, Y., Wang, Y., Jianjun, D., Hu, G., Dong, F., & Zhang, Q. (2017) · Environmental Science and Pollution Research · doi:10.1007/s11356-017-0063-6 · Cited by 8
Mouse models for mesothelioma drug discovery and development
Seastedt, K. P., Pruett, N. D., & Hoang, C. D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1867530 · Cited by 8
Lung function not affected by asbestos exposure in workers with normal Computed Tomography scan
Schikowsky, C., Felten, M. K., Eisenhawer, C., Das, M., & Kraus, T. (2017) · American Journal of Industrial Medicine · doi:10.1002/ajim.22717 · Cited by 7
Cellular defense mechanisms against asbestos fibers
Barlow, C. A., & Mossman, B. T. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1566473 · Cited by 6
The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma
Paajanen, J., Bueno, R., & Rienzo, A. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113422 · Cited by 5
Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability
Song, Y., Baxter, S. S., Dai, L., Sanders, C., Burkett, S. S., Baugher, R. N., Mellott, S. D., Young, T. B., Lawhorn, H. E., Difilippantonio, S., et al. (2022) · Cancers · doi:10.3390/cancers14133108 · Cited by 5
Self-citationHétérogénéité moléculaire des mésothéliomes pleuraux malins
Tranchant, R., Montagne, F., Jaurand, M., & Jean, D. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.11.007 · Cited by 5
Modeling Malignant Mesothelioma in Genetically Engineered Mice
Kadariya, Y., Sementino, E., Xiang, H., Kappes, D. J., & Testa, J. R. (2025) · Current Protocols · doi:10.1002/cpz1.70086 · Cited by 4
Self-citationAsbestos and the Pathophysiology of Mesothelioma
van Zandwijk, N., & Reid, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_2 · Cited by 3
Johnson, B., Lee, K. M. L., & Cheng, Y. Y. (2021) · Onco · doi:10.3390/onco1020006 · Cited by 2
Molecular Genetics of Malignant Mesothelioma
Sekido, Y. (2012) · Wiley eBooks · doi:10.1002/9780470015902.a0022448 · Cited by 2
Mesothelioma Heterogeneity: Potential Mechanisms
Felley-Bosco, E. (2019) · MDPI eBooks · doi:10.3390/books978-3-03897-474-1 · Cited by 1
Mesothelioma: An Evidence-Based Review
Goudreault, J., & Dagnault, A. (2013) · InTech eBooks · doi:10.5772/55292 · Cited by 1
Identification of BAP1 as a predisposing gene for malignant mesothelioma
Nasu, M. (2012) · ScholarSpace (University of Hawaii at Manoa) · Cited by 1
Marino, F. Z., Sabetta, R., Ronchi, A., Accardo, M., Angelillo, I. F., & Franco, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812724-7.00008-3 · Cited by 1
Pasello, G., Felley‐Bosco, E., & Remon, J. (2022) · Frontiers research topics · doi:10.3389/978-2-88974-818-1
Altérations génétiques et hétérogénéité tumorale du mésothéliome pleural malin
Quetel, L. (2018) · theses.fr (ABES) · doi:10.70675/799e029dz38c5z4b0cza50az2633e9e2d276
Biomarkers of Response to Asbestos Exposure
Mesaros, C., Weng, L., & Blair, I. A. (2017) · Current cancer research · doi:10.1007/978-3-319-53560-9_12
EGFR and related therapeutic targets in malignant pleural mesothelioma
Oguh, L. (2016) · Repository@Hull (Worktribe) (University of Hull)
Interrogating inter- and intratumour genomic heterogeneity in mesothelioma
Sharkey, A. J. (2020) · Figshare · doi:10.25392/leicester.data.12697562
Farahmand, P., Gyuraszova, K., Rooney, C., Raffo-Iraolagoitia, X. L., Jayasekera, G., Hedley, A., Johnson, E., Chernova, T., Malviya, G., Hall, H., et al. (2023) · doi:10.3389/ftox.2023.1200650.s001
Metadata
- Authors
- Altomare, D. A., Menges, C. W., Xu, J., Pei, J., Zhang, L., Tadevosyan, A., Neumann-Domer, E., Liu, Z., Carbone, M., Chudoba, I., Klein-Szanto, A. J., & Testa, J. R.
- Affiliations
- Fox Chase Cancer Center (US)
- University of Hawaiʻi at Mānoa (US)
- Corresponding author
- Testa, Joseph R.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-19
- Volume
- 6
- Issue
- 4
- Pages
- e18828
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3079727
- OpenAlex
- W2067423716
- Cited by
- 65
- References
- 13
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 6 · 2018: 5 · 2017: 8 · 2016: 4 · 2015: 6 · 2014: 3 · 2013: 7 · 2012: 5
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Journal of International Crisis and Risk Communication Research (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health (5p01ca114047-05)
- National Cancer Institute (CA009035, T32CA009035, P01CA-114047, P30CA006927, CA06927)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Keywords
- p16INK4a, p14ARF, malignant mesothelioma, asbestos carcinogenesis, tumor suppressor, INK4A, ARF, biallelic inactivation, p19ARF, carcinogenesis, mouse model
- MeSH terms
- Alleles, Animals, Asbestos, Humans, Mesothelioma, Precancerous Conditions, Cyclin-Dependent Kinase Inhibitor p16, Gene Silencing, Tumor Suppressor Protein p14ARF, Chromosomes, Mammalian, Mice, Genetic Loci
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.